116 related articles for article (PubMed ID: 7190063)
1. Maintenance of MOPC 104E myeloma in plateau phase.
Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
[TBL] [Abstract][Full Text] [Related]
2. cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
Ghanta VK; Jones MT; Woodard DA; Durant JR; Hiramoto RN
Cancer Res; 1977 Mar; 37(3):771-4. PubMed ID: 851480
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Hiramoto R; Ghanta V; Durant JR
Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
[TBL] [Abstract][Full Text] [Related]
4. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
Ghanta VK; Hiramoto NS; Hiramoto RN
Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
[TBL] [Abstract][Full Text] [Related]
5. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
Fenton MR; Havas HF
J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
7. A murine plasmacytoma model for screening active drugs for human myeloma.
Hiramoto RN; Ghanta VK; Durant JR; Hiramoto NS
Cancer Clin Trials; 1980; 3(4):395-402. PubMed ID: 7428144
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
[TBL] [Abstract][Full Text] [Related]
10. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
[TBL] [Abstract][Full Text] [Related]
11. MOPC 104E plasmacytoma functional heterogeneity and maturational potential in culture.
Miura T; Hiramoto RN; Ghanta VK
Cancer Res; 1983 Mar; 43(3):953-8. PubMed ID: 6825114
[TBL] [Abstract][Full Text] [Related]
12. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
Miura T; Ghanta VK; Hiramoto RN
Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
[TBL] [Abstract][Full Text] [Related]
13. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
[TBL] [Abstract][Full Text] [Related]
14. Induction of the plateau phase and rescue of MOPC 104E by nonspecific immunization.
Ghanta VK; Shrestha K; Hiramoto RN
Cancer Invest; 1986; 4(6):525-33. PubMed ID: 3828861
[TBL] [Abstract][Full Text] [Related]
15. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
17. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
Valeriote F; Grates H
J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
[TBL] [Abstract][Full Text] [Related]
18. In vitro effect of monoclonal anti-idiotype antibodies (anti-M104E) on MOPC 104E myeloma cells.
Kodama K; Ghanta VK; Hiramoto RN; Stohrer RC; Kearney JF
Cancer Res; 1986 Mar; 46(3):1250-4. PubMed ID: 3484677
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
